Observational report notes increase in meningococcal disease cases among US persons with HIV in 2022

An observational report from the United States described an increase in meningococcal disease cases among persons with HIV during 2022 compared to previous years. The study type was observational, and the specific sample size was not reported. The report did not specify the intervention or exposure being studied, nor did it detail the comparator beyond 'previous years.' The primary outcome was an increase in meningococcal disease cases. The main result was simply reported as an 'increase,' with no effect size, absolute case numbers, p-values, or confidence intervals provided. No data on safety, adverse events, or tolerability were reported. Key limitations include the purely descriptive nature of the report, the lack of statistical measures to quantify the increase, and the absence of data on the magnitude of the change. The generalizability of the finding beyond the 2022 US data is unclear. In terms of practice relevance, this report serves as a signal for clinicians to be aware of a potential association. However, given the lack of quantitative data and the observational design, it cannot inform changes to screening, prevention, or treatment protocols. The report explicitly notes this is an association, not evidence of causation.